Wave Life Sciences' Obesity Drug WVE-007 Shows Encouraging Early Results; Shares Surge 70%

Wave Life Sciences Ltd. (WVE) on Monday reported positive interim results from its first-in-human INLIGHT trial evaluating WVE-007 for obesity, sending the company's shares up more than 70% in pre-market trading.Following a single 240 mg dose, WVE-007 improved body composition at three months versus baseline, with a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass, while no significant changes were observed in the placebo group. The treatment was generall ...